歌禮製藥(01672.HK)附屬候選藥物獲批開展中國臨床試驗
歌禮製藥(01672.HK)公布,國家藥品監督管理局(NMPA)已批准ASC42開展用於治療非酒精性脂肪性肝炎(NASH)的臨床試驗。ASC42是旗下全資附屬甘萊製藥的候選藥物。
ASC42是一款由甘萊完全自主研發、有望成為同類最佳的新型高效選擇性非甾類法尼醇X受體(FXR)激動劑。ASC42口服片劑由甘萊專有製劑技術開發,具有室溫下穩定的特點。ASC42既可作為單藥使用,也可與甲狀腺激素β受體(THR-β)激動劑ASC41或脂肪酸合成(酉每)(FASN)抑制劑ASC40聯合使用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.